-- Company Enters Lucrative Markets of Panama, Bermuda and Aruba with Marketing Partner --
SANTA MONICA, Calif., June 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which earlier this month announced sales operation expansion into the European Union, said today it has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is expected to target hospitals and obstetricians/gynecologists in those areas. Cord Blood will receive revenue from the sale of cord blood processing and storage services sold to each family. Marketing of such services will commence immediately.
"We are excited to begin marketing our cord blood processing and storage services in areas where we have the first-mover advantage," said founder and CEO Matthew Schissler. "We will be the first party offering such services in Bermuda and Aruba, and the second party in Panama. Based upon the experience in North America, we believe that being first in the market will provide us with compelling advantages. We see the storage of stem cells internationally as potentially very profitable. While the size of these overall countries is relatively small, given the highly attractive demographics of their population we believe the opportunities could be lucrative. The advantages of storing stem cells at birth, and at other times in life, are becoming well known worldwide."
Panama, with a population of 3.3 million, has become an international business center in Central America, with a fast growing economy and the highest per capita consumer spending in the region. Aruba, an affluent island in the southern Caribbean, is overseen by the Netherlands, while Bermuda, a British territory in the North Atlantic, has previously had the world's highest GDP per capita.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 email@example.com
|SOURCE Cord Blood America, Inc.|
Copyright©2009 PR Newswire.
All rights reserved